Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266559 | 0.86 | JUN (0.50) | JUNNFKB1ABCG2PDE4APDE4B | |
| SCHEMBL6093637 | 0.80 | F3 (0.55) | MAPTLMNASMN1; SMN2ATMMEN1 | |
| SCHEMBL9256671 | 0.80 | JUN (0.77) | JUNNFKB1ABCG2PDE4APDE4B | |
| SCHEMBL9256668 | 0.80 | JUN (0.77) | JUNNFKB1ABCG2PDE4APDE4B | |
| SCHEMBL4732088 | 0.79 | MEN1 (0.45) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5505977 | 0.79 | MAOB (0.53) | JUNNFKB1ABCG2MAPTLMNA | |
| SCHEMBL5504507 | 0.78 | MEN1 (0.50) | ABCG2MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL4728511 | 0.78 | ALDH1A1 (0.61) | ABCG2MAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL4731550 | 0.77 | ALDH1A1 (0.47) | MAPTLMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL4726961 | 0.77 | KMT2A (0.43) | MAPTLMNASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | claimed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | claimed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | claimed |
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | PMP22, ADCYAP1R1, CYP11B2 | JUN 3678/4885NFKB1 2947/4885ABCG2 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.